Latest Breaking News On - Pharma europe - Page 6 : comparemela.com

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected

Bayer unveils first look at its post-Xarelto, post-Eylea life—and it s better than expected
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Stefan oelrichPharma europePharma marketingDigital pharmaWall streetபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாசுவர் தெரு

NantKwest starts dosing in subcutaneous, sublingual and oral COVID-19 vaccine trials

Patrick Soon-Shiong, M.D., executive chairman of ImmunityBio and NantKwest (NantKwest) ImmunityBio and NantKwest have begun dosing participants with subcutaneous, sublingual and oral COVID-19 vaccine candidates. The trials are designed to determine which combination of routes of administration holds the most potential. While a clutch of COVID-19 vaccines are now in commercial use around the world, the potential for the coronavirus to become a pathogen that continues to circulate for years means there may be a long-term opportunity for prophylactics. ImmunityBio and NantKwest are part of a group of vaccine developers working to seize that opportunity. The partners recently took a step forward when dosing began in clinical trials in the U.S. and South Africa. Two U.S. phase 1b clinical trials are evaluating the effect of giving sublingual or oral vaccines in addition to a subcutaneous formulation. Six subjects have been dosed in each U.S. trial.

South africaSouth africanPharma europePharma marketingDigital pharmaPatrick soon shiongCorona virusCovid 19Oral vaccinesSubcutaneous drug deliveryDrug deliveryபார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாகொரோனா வைரஸ்வாய்வழி தடுப்பு மருந்துகள்

Johnson & Johnson runs into vaccine supply issues in Europe, threatening second-quarter delivery pledge: Reuters

Mar 9, 2021 10:30am Johnson & Johnson is one of several companies working around the clock to scale up vaccine supply. (Kunal Mahto/iStock/Getty Images Plus/Getty Images) Johnson & Johnson execs have assured investors and officials that the company is comfortable hitting its vaccine delivery targets. But with its U.S. rollout underway, the pharma giant has run into some supply problems in Europe, Reuters reports. J&J’s shot isn’t yet authorized in Europe, but the company has been gearing up to supply a promised 55 million doses during the second quarter and now it s hitting some snags, an official involved in supply talks told the news service. The shot is expected to win an EU authorization in the coming days, Reuters reports, and vaccinations in the bloc could start next month.

Sanofi pasteurJoe wolkReig jofrePharma europePharma marketingDigital pharmaJohnson ampEuropean commissionCovid 19சனோஃபி பாஸ்டர்ஓஹோ வோல்க்பார்மா யூரோப்பார்மா சந்தைப்படுத்தல்டிஜிட்டல் பார்மாஜான்சன் ஆம்ப்ஐரோப்பிய தரகு

Ultrarare disease specialists top 2021 s pricey drugs list, but Takeda, Merck KGaA meds rank, too

Mar 9, 2021 12:12pm Eiger BioPharmaceuticals Zokinvy, recently approved by the FDA for ultrarare rapid-aging diseases that affect an estimated 600 children worldwide, is the most expensive drug in U.S. pharmacies in 2021, according to GoodRx.(Jacoblund) Eiger BioPharmaceuticals in November snagged FDA clearance for Zokinvy for ultra-rare rapid-aging diseases that affect an estimated 600 people worldwide. Orphan drugs that treat small patient populations typically come with high prices, but Zokinvy’s sticker price now beats them all in U.S. pharmacies. At an estimated monthly price of $86,000, or more than $1 million a year, Zokinvy’s now the most expensive pharmacy drug in the U.S. as of February, according to a list compiled by GoodRx. The ranking focuses on monthly prices and doesn’t include drugs administered by doctors.

Eiger onecareZokinvy orladeyoAmryt pharmaPharma europeMerck kgaMerck kgaaMerck coBristol myers squibbEiger biopharmaceuticalsPharma marketingDigital pharmaBiocryst pharmaceuticalPharmaceutical qinlockMyers squibbViekira pakAgios pharmaceuticals

As viral vector demand surges, fledgling CDMO Matica establishes a beachhead in Texas

Mar 8, 2021 10:23am There s a ready market for viral vectors. Matica, a new CDMO and a subsidiary of South Korea-based CHA Biotech, will soon be poised to help meet the demand. (Harvard University) A lack of global capacity to produce cell and gene therapies has been exacerbated by an even more pressing need: to develop and manufacture coronavirus vaccines. So it appears the timing is right for Matica Biotechnology, a developer and producer of viral vectors, to put down roots in the United States. The brand-new CDMO has teamed up with Texas A&M University and its advanced manufacturing center and started work on a 25,000 square-foot viral vector plant near the university s College Station campus.

United statesSan franciscoPharma europeTexasam universityMatica biotechnologyCollege stationPharma marketingDigital pharmaAndrew arrageSouth korea basedAdvanced developmentCha biotechViral vectorsManufacturing plantGene therapy manufacturingஒன்றுபட்டது மாநிலங்களில்